Results 21 to 30 of about 7,581 (239)

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012) [PDF]

, 2013
Ceftolozane/tazobactam, a novel antimicrobial agent with activity against Pseudomonas aeruginosa (including drug-resistant strains) and other common Gram-negative pathogens (including most extended-spectrum-beta-lactamase [ESBL]-producing ...
David J. Farrell, Robert K. Flamm, Hélio S. Sader, Ronald N. Jones   +3 more
openalex   +4 more sources

Ceftolozane/Tazobactam [PDF]

Hospital Pharmacy, 2015
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Dennis J, Cada, Jesse, Wageman, Danial E, Baker, Terri L, Levien   +3 more
openaire   +4 more sources

Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry

Journal of Global Antimicrobial Resistance, 2021
: Objectives: Ceftolozane/tazobactam is a cephalosporin/β-lactamase inhibitor combination with activity against Gram-negative bacilli. Here we report the use of ceftolozane/tazobactam in Canada using a national registry. Methods: The CLEAR registry uses
George G. Zhanel, Rita Dhami, Melanie Baxter, Justin Kosar, Carlos Cervera, Neal Irfan, Rosemary Zvonar, Sergio Borgia, Jean-Francois Tessier, Gordon Dow, Robert Ariano, Maxime Dube, Michel Savoie, Matteo Bassetti, Andrew Walkty, James A. Karlowsky   +15 more
doaj   +1 more source

The safety of ceftolozane-tazobactam for the treatment of acute bacterial infections: a systemic review and meta-analysis

Therapeutic Advances in Drug Safety, 2021
Objective(s): The aim of this study was to conduct a meta-analysis to assess the clinical safety of ceftolozane-tazobactam for the treatment of acute bacterial infections in adult patients.
Li-Ting Wang, Wei-Ting Lin, Chih-Cheng Lai, Ya-Hui Wang, Cheng-Hsin Chen, Yen-Teh Chang, Chao-Hsien Chen, Cheng-Yi Wang   +7 more
doaj   +1 more source

Treatment of multidrug-resistant Pseudomonas aeruginosa bacteremia using ceftolozane-tazobactam-based or colistin-based antibiotic regimens: A multicenter retrospective study

Journal of Infection and Public Health, 2022
Background: Ceftolozane-tazobactam is an emerging ‎treatment for severe infections caused by multidrug-resistant (MDR) Pseudomonas ‎aeruginosa. However, limited ‎data support its use in bacteremia treatment.
Hakeam A. Hakeam, Ghadi Askar, Khalid Al Sulaiman, Reem Mansour, Maha M. Al Qahtani, Dana Abbara, Nada Aldhayyan, Nariman Dyab, Liyan Afaneh, Muna Islami, Zainab Al Duhailib   +10 more
doaj   +1 more source

Evaluation of in vitro activity of ceftolozane-tazobactam in combination with other classes of antibacterial agents against Enterobacterales and Pseudomonas aeruginosa—the EM200 study

New Microbes and New Infections, 2021
Ceftolozane-tazobactam is a cephalosporin/β-lactamase inhibitor combination developed for use against some β-lactam- and multidrug-resistant Gram-negative organisms.
J. Belkhair, S. Nachat, S. Rouhi, H. Ouassif, S. Abbassi, N. Soraa   +5 more
doaj   +1 more source

Influence of extracorporeal membrane oxygenation on the pharmacokinetics of ceftolozane/tazobactam: an ex vivo and in vivo study

Journal of Translational Medicine, 2020
Background Extracorporeal membrane oxygenation (ECMO) is increasingly used in intensive care units and can modify drug pharmacokinetics and lead to under-exposure associated with treatment failure. Ceftolozane/tazobactam is an antibiotic combination used
Camille Mané, Clément Delmas, Jean Porterie, Géraldine Jourdan, Patrick Verwaerde, Bertrand Marcheix, Didier Concordet, Bernard Georges, Stéphanie Ruiz, Peggy Gandia   +9 more
doaj   +1 more source

Pharmacokinetics of continuous infusion ceftolozane/tazobactam in two patients with extensive total body surface area burns. [PDF]

Pharmacotherapy
Abstract Introduction Treatment of infections in patients with burn injuries is challenging due to altered antimicrobial pharmacokinetics. Continuous infusion β‐lactam therapy may be a useful antimicrobial stewardship strategy to improve pharmacodynamic target attainment in this population.
Olivet JD, Amerson-Brown M, Calix JJ, Graffice E, Kilpatrick T, Roenfanz HF, Nicolau DP, Kuti JL, Brown ML.   +8 more
europepmc   +2 more sources

Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia [PDF]

, 2020
Objectives: Ceftolozane/tazobactam is approved for hospital-acquired/ventilator-associated bacterial pneumonia at double the dose (i.e. 2 g/1 g) recommended for other indications.
Adedoyin, Adedayo, Caro, Luzelena, De Waele, Jan, Gadzicki, Elaine, Kuti, Joseph L, Larson, Kajal B, Nicolau, David P, Rhee, Elizabeth G, Yu, Brian, Zeng, Zhen   +9 more
core   +1 more source

Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem

Critical Care, 2022
Background Ceftolozane/tazobactam, a combination antibacterial agent comprising an anti-pseudomonal cephalosporin and β-lactamase inhibitor, is approved for the treatment of hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) in ...
Marin H. Kollef, Jean-François Timsit, Ignacio Martin-Loeches, Richard G. Wunderink, Jennifer A. Huntington, Erin H. Jensen, Brian Yu, Christopher J. Bruno   +7 more
doaj   +1 more source